Table 1.
Wierda et al, 200716 | Wierda et al, 201119 | Haferlach et al, 201020 | Rossi et al, 201321 | Pflug et al, 201417 | CLL-IPI working group, 2016 | |
---|---|---|---|---|---|---|
Number of patients | 1674 | 930 | 399 | 637 | 1948 | 3472 |
Application | All stages, previously untreated | Early stage only | Early stage only | All stages, previously untreated | All stages, previously untreated | All stages, previously untreated |
Clinical implications | OS and TTT | TTT | oS and TTT | OS | OS | OS |
Factors included | Age, β2-M, ALC, Hb, gender, Rai stage, involved LNA | unmutated IGHV, diameter palpable LN, del(11q) or del(17p), involved LNA, LDH | Age, WBC, del(17p), unmutated IGHV, IGHV locus translocation, N cytogenetic aberrations | TP53 del/mut, BIRC3 del/mut, NOTCH1 mut, SF3B1 mut, del(11q), trisomy 12 normal genetics, del(13q) | age, gender, ECOG, thymidine kinase, β2-M, unmutated IGHV, del(17p), del(11q) | TP53 del/mut, unmutated IGHV, β2-M, clinical stage, age |
Validation | Concordance index | Internal | None | Internal | Internal and external | Internal and external |
Definition of risk groups | Low Intermediate High |
Prognostic nomogram | Favorable Intermediate Unfavorable | Very low Low Intermediate High |
Low Intermediate High Very high |
Low Intermediate High Very high |
ALC, absolute lymphocyte count; β2-M, beta2-microglobulin; Hb, hemoglobin; LN, lymph node; LNA, lymph node areas; WBC, white blood cell count.